BAM
PPBT

Belpointe Asset Management’s Purple Biotech PPBT Stock Holding History

Belpointe Asset Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13
Closed -$4.65K – 2610
2023
Q1 		$4.65K Hold
13
– – ﹤0.01% 3040
2022
Q4 		$3.59K Buy
+13
New +$4.99K ﹤0.01% 3046

Other funds holding PPBT

KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return
WAOI
Wealth Advisors of Iowa West Des Moines, Iowa $369M AUM 18.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
FA
Fiduciary Alliance Greenville, South Carolina $1.48B AUM 24.99% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Belpointe Asset Management's PPBT Position: Q2 2023 in Review

Belpointe Asset Management sold out of Purple Biotech (PPBT) in Q2 2023, closing a stake of 13 shares — an estimated $4.65K sold.

Belpointe Asset Management first reported a position in PPBT in Q4 2022 and held it in 2 quarters. The position peaked at $4.65K in Q1 2023. 15 funds tracked by Wall St. Rank hold PPBT as of Q2 2023.

  • Belpointe Asset Management reported no remaining Purple Biotech position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 13 Purple Biotech shares in Q2 2023, an estimated $4.65K.
  • Belpointe Asset Management first reported a position in Purple Biotech in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Purple Biotech position peaked at $4.65K in Q1 2023.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.